What are the latest WHO guidelines for the management of enteric fever, including recommended drugs and dosing regimens for adults and children?

Latest WHO Guidelines on Enteric Fever Management

Based on the most recent WHO guidance from 2024, treatment of enteric fever should be tailored to local resistance patterns, with azithromycin or ceftriaxone as preferred first-line agents in most settings, particularly given widespread fluoroquinolone resistance in South Asia. 1

Current WHO Recommendations by Resistance Pattern

For Fully Susceptible Salmonella Typhi:

• First-line: Fluoroquinolone (ofloxacin or ciprofloxacin)
• Alternatives: Chloramphenicol, amoxicillin, or trimethoprim-sulfamethoxazole (if organism remains sensitive) 1

For Multidrug-Resistant Strains:

• First-line: Fluoroquinolone or cefixime
• Alternatives: Azithromycin or cefixime 1

For Quinolone-Resistant Strains (Common in South Asia):

• First-line: Azithromycin or ceftriaxone
• Alternative: Cefixime 1

For Extensively Drug-Resistant (XDR) Typhoid:

• Required treatment: Azithromycin and/or meropenem 2

Pediatric-Specific Guidance

The 2012 WHO guidelines for children recommend:

• First-line: Fluoroquinolone (ciprofloxacin, gatifloxacin, ofloxacin, or perfloxacin)
• Second-line (for poor response): Third-generation cephalosporin (e.g., ceftriaxone) or azithromycin 1

Critical Evidence-Based Considerations

Fluoroquinolone resistance has fundamentally changed treatment paradigms. The evidence shows that fluoroquinolone MICs have risen significantly since 2005, particularly in South Asia, correlating with increasing fever clearance times and treatment failures 3. In Nepal, only 12% of isolates remained ciprofloxacin-susceptible by 2013 4.

Azithromycin demonstrates superior outcomes in comparative trials. Research shows azithromycin has lower clinical failure rates (OR 0.48,95% CI 0.26-0.89) and shorter hospital stays compared to fluoroquinolones, plus lower relapse rates (OR 0.09,95% CI 0.01-0.70) compared to ceftriaxone 1.

Ceftriaxone remains highly effective with universal susceptibility. All organisms tested between 2005-2014 remained susceptible to ceftriaxone, making it a reliable option when resistance patterns are unknown 3. However, ceftriaxone may have higher relapse rates (11%) when used as monotherapy, particularly if discontinued before 4 days post-defervescence 4.

Practical Treatment Algorithm

1. Obtain blood cultures before starting antibiotics (bone marrow culture if blood culture negative but high suspicion)

2. Assess geographic origin:

   • South Asia origin: Avoid fluoroquinolones empirically → Use azithromycin or ceftriaxone
   • Pakistan origin: Consider XDR typhoid → Use azithromycin + meropenem
   • Other regions: May use fluoroquinolones if local susceptibility confirmed

3. Choose route based on severity:

   • Outpatient/mild: Oral azithromycin or oral fluoroquinolone (if susceptible)
   • Inpatient/moderate-severe: IV ceftriaxone

4. Duration considerations:

   • Continue ceftriaxone for >4 days after defervescence to prevent relapse 4
   • Switch to oral fluoroquinolone if susceptibility confirmed and fever persists >7 days on ceftriaxone

Important Caveats

The 2024 WHO guidance acknowledges a critical evidence gap: older antibiotics (ampicillin/amoxicillin, trimethoprim-sulfamethoxazole, chloramphenicol) and cefixime lack systematic review support despite previous 2003 WHO recommendations 1. Interestingly, susceptibility to these older agents has re-emerged in some regions 5, potentially making them viable options where confirmed susceptible.

Cefixime performs less well than other options. Clinical failure, microbiological failure, and relapse rates are all increased with cefixime compared to fluoroquinolones (RR 13.39,4.07, and 4.45 respectively), with longer fever clearance times 5.

Combination therapy is under investigation. The ongoing ACT-SA trial is exploring azithromycin plus cefixime to target both intracellular and extracellular bacteria 2, which may become relevant for XDR cases.

Chronic carriers require prolonged treatment with limited evidence to guide duration, though specific guidance is lacking in current WHO recommendations 2.

The key message: Local resistance patterns must guide empiric therapy, with South Asian cases requiring avoidance of fluoroquinolones and preference for azithromycin or ceftriaxone 6.